The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Northstrive Biosciences has submitted a pre-Investigational New Drug, or pre-IND, meeting request to the FDA for EL-22, a novel myostatin asset ...